{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:07:40Z","timestamp":1761718060753,"version":"3.40.3"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s11883-008-0020-4","type":"journal-article","created":{"date-parts":[[2008,4,5]],"date-time":"2008-04-05T08:27:10Z","timestamp":1207384030000},"page":"134-141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["PPAR\u03b3 agonists and coronary atherosclerosis"],"prefix":"10.1007","volume":"10","author":[{"given":"Melanie S.","family":"Sulistio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne","family":"Zion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nandish","family":"Thukral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Chilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,4,6]]},"reference":[{"key":"20_CR1","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.2337\/dc06-0560","volume":"29","author":"R.F. Hamman","year":"2006","unstructured":"Hamman RF, Wing RR, Edelstein SL, et al.: Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006, 29:2102\u20132107.","journal-title":"Diabetes Care"},{"key":"20_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1172\/JCI28003","volume":"116","author":"R.K. Semple","year":"2006","unstructured":"Semple RK, Chaterjee VK, O\u2019Rahilly S: PPARa and human metabolic disease. J Clin Invest 2006, 116:581\u2013589.","journal-title":"J Clin Invest"},{"key":"20_CR3","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2337\/diabetes.46.8.1319","volume":"46","author":"D. Auboeuf","year":"1997","unstructured":"Auboeuf D, Rieusset J, Fajas L, et al.: Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997, 46:1319\u20131327.","journal-title":"Diabetes"},{"key":"20_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.cardiores.2006.08.023","volume":"73","author":"B.N. Finck","year":"2007","unstructured":"Finck BN: The PPAR regulatory system in cardiac physiology and disease. Cardiovasc Res 2007, 73:269\u2013277.","journal-title":"Cardiovasc Res"},{"key":"20_CR5","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1073\/pnas.90.4.1440","volume":"90","author":"K.L. Gearing","year":"1993","unstructured":"Gearing KL, G\u00f6ttlicher M, Teboul M, et al.: Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci U S A 1993, 90:1440\u20131444.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"20_CR6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/j.1460-2075.1992.tb05072.x","volume":"2","author":"J.D. Tugwood","year":"1992","unstructured":"Tugwood JD, Issemann I, Anderson RG, et al.: The mouse peroxisome proliferator activated receptor recognizes a response element in the 5\u2032 flanking sequence of the rat acyl CoA oxidase gene. EMBO J 1992, 2:433\u2013439.","journal-title":"EMBO J"},{"issue":"Pt1","key":"20_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1042\/0264-6021:3630157","volume":"363","author":"A.M. Krogsdam","year":"2002","unstructured":"Krogsdam AM, Nielsen CA, Neve S, et al.: Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor delta-mediated transactivation. Biochem J 2002, 363(Pt 1):157\u2013165.","journal-title":"Biochem J"},{"key":"20_CR8","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/01.RES.84.9.1085","volume":"84","author":"W. Dichtl","year":"1999","unstructured":"Dichtl W, Nilsson L, Goncalves I, et al.: Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. Circ Res 1999, 84:1085\u20131094.","journal-title":"Circ Res"},{"key":"20_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/34178","volume":"391","author":"M. Ricote","year":"1998","unstructured":"Ricote M, Li AC, Willson TM, et al.: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79\u201382.","journal-title":"Nature"},{"key":"20_CR10","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1161\/01.RES.83.11.1097","volume":"83","author":"N. Marx","year":"1998","unstructured":"Marx N, Sch\u00f6nbeck U, Lazar MA, et al.: Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998, 83:1097\u2013103.","journal-title":"Circ Res"},{"key":"20_CR11","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1161\/01.CIR.102.15.1834","volume":"102","author":"K. Takeda","year":"2000","unstructured":"Takeda K, Ichiki T, Tokunou T, et al.: Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 2000, 102:1834\u20131839.","journal-title":"Circulation"},{"key":"20_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0014-5793(99)00624-9","volume":"452","author":"S. Goetze","year":"1999","unstructured":"Goetze S, Xi XP, Graf K, et al.: Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1\/2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Lett 1999, 452:277\u2013282.","journal-title":"FEBS Lett"},{"key":"20_CR13","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.2337\/diabetes.53.11.2735","volume":"53","author":"C.C. Wang","year":"2004","unstructured":"Wang CC, Goalstone ML, Draznin B: Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 2004, 53:2735\u20132740.","journal-title":"Diabetes"},{"issue":"1A","key":"20_CR14","doi-asserted-by":"publisher","first-page":"21J","DOI":"10.1016\/S0002-9149(99)00353-7","volume":"84","author":"W.A. Hsueh","year":"1999","unstructured":"Hsueh WA, Law RE: Insulin signaling in the arterial wall. Am J Cardiol 1999, 84(1A):21J\u201324J.","journal-title":"Am J Cardiol"},{"key":"20_CR15","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.2337\/diabetes.52.8.1943","volume":"52","author":"Y. Miyazaki","year":"2003","unstructured":"Miyazaki Y, He H, Mandarino LJ, et al.: Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes 2003, 52:1943\u20131950.","journal-title":"Diabetes"},{"key":"20_CR16","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1210\/jc.87.4.1555","volume":"87","author":"S.A. Arslanian","year":"2002","unstructured":"Arslanian SA, Lewy V, Danadian K, et al.: Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia\/insulin resistance. J Clin Endocrinol Metab 2002, 87:1555\u20131559.","journal-title":"J Clin Endocrinol Metab"},{"key":"20_CR17","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1056\/NEJM199602293340906","volume":"334","author":"C.J. Bailey","year":"1996","unstructured":"Bailey CJ, Turner RC: Metformin. N Engl J Med 1996, 334:574\u2013579.","journal-title":"N Engl J Med"},{"key":"20_CR18","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.2337\/diabetes.52.6.1311","volume":"52","author":"J.K. Kim","year":"2003","unstructured":"Kim JK, Fillmore JJ, Gavrilova O, et al.: Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP\/F-1 fatless mice. Diabetes 2003, 52:1311\u20131318.","journal-title":"Diabetes"},{"key":"20_CR19","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1172\/JCI17305","volume":"112","author":"A.W. Norris","year":"2003","unstructured":"Norris AW, Chen L, Fisher SJ, et al.: Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 2003, 112:608\u2013618.","journal-title":"J Clin Invest"},{"key":"20_CR20","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/nm956","volume":"9","author":"A.L. Hevener","year":"2003","unstructured":"Hevener AL, He W, Barak Y, et al.: Muscle-specific PPARg deletion causes insulin resistance. Nat Med 2003, 9:1491\u20131497.","journal-title":"Nat Med"},{"key":"20_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0022-2143(96)90111-0","volume":"128","author":"S. Sethi","year":"1996","unstructured":"Sethi S, Eastman AY, Eaton JW: Inhibition of phagocyteendothelium interactions by oxidized fatty acids: a natural anti-inflammatory mechanism?\n                           J Lab Clin Med 1996, 128:27\u201338.","journal-title":"J Lab Clin Med"},{"key":"20_CR22","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1182\/blood-2002-01-0316","volume":"100","author":"S. Sethi","year":"2002","unstructured":"Sethi S, Ziouzenkova O, Ni H, et al.: Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha. Blood 2002, 100:1340\u20131346.","journal-title":"Blood"},{"key":"20_CR23","doi-asserted-by":"crossref","first-page":"H2248","DOI":"10.1152\/ajpheart.01138.2002","volume":"285","author":"B. Noh\u00e9","year":"2003","unstructured":"Noh\u00e9 B, Johannes T, Dieterich HJ: Antiinflammatory effects of omega-3 fatty acids vary at different stages of inflammation. Am J Physiol Heart Circ Physiol 2003, 285:H2248\u2013H2249.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"20_CR24","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.2337\/diabetes.54.12.3496","volume":"54","author":"A.J. Murray","year":"2005","unstructured":"Murray AJ, Panagia M, Hauton D, et al.: Plasma free fatty acids and peroxisome proliferator-activated receptor alpha in the control of myocardial uncoupling protein levels. Diabetes 2005, 54:3496\u20133502.","journal-title":"Diabetes"},{"key":"20_CR25","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1161\/01.CIR.96.7.2190","volume":"96","author":"S. Neubauer","year":"1997","unstructured":"Neubauer S, Horn M, Cramer M, et al.: Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997, 96:2190\u20132196.","journal-title":"Circulation"},{"key":"20_CR26","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R. Belfort","year":"2006","unstructured":"Belfort R, Harrison SA, Brown K, et al.: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297\u20132307.","journal-title":"N Engl J Med"},{"key":"20_CR27","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1172\/JCI107235","volume":"52","author":"G. Schlierf","year":"1973","unstructured":"Schlierf G, Dorow E: Diurnal patterns of triglycerides, free fatty acids, blood sugar, and insulin during carbohydrate-induction in man and their modification by nocturnal suppression of lipolysis. J Clin Invest 1973, 52:732\u2013740.","journal-title":"J Clin Invest"},{"issue":"3","key":"20_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/mrm.10372","volume":"49","author":"L.S. Szczepaniak","year":"2003","unstructured":"Szczepaniak LS, Dobbins RL, Metzger GJ, et al.: Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med 2003, 49(3):417\u2013423.","journal-title":"Magn Reson Med"},{"issue":"1\u20136","key":"20_CR29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/0960-0760(95)00093-F","volume":"53","author":"C. Bocos","year":"1995","unstructured":"Bocos C, G\u00f6ttlicher M, Gearing K, et al.: Fatty acid activation of peroxisome proliferator-activated receptor (PPAR). J Steroid Biochem Mol Biol 1995, 53(1\u20136):467\u2013473.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"20_CR30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/ajcn\/75.2.213","volume":"75","author":"V.M. Rodr\u00edguez","year":"2002","unstructured":"Rodr\u00edguez VM, Portillo MP, Pic\u00f3 C, et al.: Olive oil feeding up-regulates uncoupling protein genes in rat brown adipose tissue and skeletal muscle. Am J Clin Nutr 2002, 75:213\u2013220.","journal-title":"Am J Clin Nutr"},{"key":"20_CR31","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7326\/0003-4819-144-7-200604040-00011","volume":"144","author":"J.M. McGavock","year":"2006","unstructured":"McGavock JM, Victor RG, Unger RH, et al.: Adiposity of the heart, revisited. Ann Intern Med 2006, 144:517\u2013524.","journal-title":"Ann Intern Med"},{"key":"20_CR32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/01.ATV.21.3.365","volume":"21","author":"A.R. Collins","year":"2001","unstructured":"Collins AR, Meehan WP, Kintscher U, et al.: Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptordeficient mice. Arterioscler Thromb Vasc Biol 2001, 21:365\u2013371.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"20_CR33","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1210\/en.139.12.5034","volume":"139","author":"J.R. Zierath","year":"1998","unstructured":"Zierath JR, Ryder JW, Doebber T, et al.: Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. Endocrinology 1998, 139:5034\u20135041.","journal-title":"Endocrinology"},{"issue":"Suppl1","key":"20_CR34","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.2337\/diabetes.53.2007.S66","volume":"53","author":"S.Y. Kim","year":"2004","unstructured":"Kim SY, Kim HI, Park SK, et al.: Liver glucokinase can be activated by peroxisome proliferator-activated receptorgamma. Diabetes 2004, 53(Suppl 1):S66\u2013S70.","journal-title":"Diabetes"},{"key":"20_CR35","doi-asserted-by":"publisher","first-page":"32048","DOI":"10.1074\/jbc.274.45.32048","volume":"274","author":"P. Delerive","year":"1999","unstructured":"Delerive P, De Bosscher K, Besnard S, et al.: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative crosstalk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999, 274:32048\u201332054.","journal-title":"J Biol Chem"},{"key":"20_CR36","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1161\/01.ATV.0000160340.72641.87","volume":"25","author":"M.P. de Winther","year":"2005","unstructured":"de Winther MP, Kanters E, Kraal G, et al.: Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol 2005, 25:904\u2013914.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"20_CR37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1161\/01.ATV.0000044461.01844.C9","volume":"23","author":"D.S. Calnek","year":"2003","unstructured":"Calnek DS, Mazzella L, Roser S, et al.: Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003, 23:52\u201357.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"20_CR38","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nri912","volume":"2","author":"R.A. Daynes","year":"2002","unstructured":"Daynes RA, Jones DC.: Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002, 2:748\u2013759.","journal-title":"Nat Rev Immunol"},{"key":"20_CR39","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1677\/joe.0.1690453","volume":"169","author":"P. Delerive","year":"2001","unstructured":"Delerive P, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001, 169:453\u2013459.","journal-title":"J Endocrinol"},{"key":"20_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/34178","volume":"391","author":"M. Ricote","year":"1998","unstructured":"Ricote M, Li AC, Willson TM, et al.: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79\u201382.","journal-title":"Nature"},{"key":"20_CR41","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/01.CIR.101.3.235","volume":"101","author":"V. Pasceri","year":"2000","unstructured":"Pasceri V, Wu HD, Willerson JT, et al.: Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000, 101:235\u2013248.","journal-title":"Circulation"},{"key":"20_CR42","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/01.ATV.21.3.372","volume":"21","author":"Z. Chen","year":"2001","unstructured":"Chen Z, Ishibashi S, Perrey S, et al.: Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 2001, 21:372\u2013377.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"20_CR43","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1172\/JCI200523219","volume":"115","author":"K. Nagashima","year":"2005","unstructured":"Nagashima K, Lopez C, Donovan D, et al.: Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2005, 115:1323\u20131332.","journal-title":"J Clin Invest"},{"key":"20_CR44","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2337\/diacare.28.7.1547","volume":"28","author":"R.B. Goldberg","year":"2005","unstructured":"Goldberg RB, Kendall DM, Deeg MA, et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28:1547\u20131554.","journal-title":"Diabetes Care"},{"key":"20_CR45","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1161\/01.RES.0000258023.76515.a3","volume":"100","author":"H.J. Ting","year":"2007","unstructured":"Ting HJ, Stice JP, Schaff UY, et al.: Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha. Circ Res 2007, 100:381\u2013390.","journal-title":"Circ Res"},{"key":"20_CR46","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/jama.298.3.299","volume":"298","author":"B.G. Nordestgaard","year":"2007","unstructured":"Nordestgaard BG, Benn M, Schnohr P, et al.: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299\u2013308.","journal-title":"JAMA"},{"key":"20_CR47","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1161\/01.STR.0000257974.06317.49","volume":"38","author":"R. Wilcox","year":"2007","unstructured":"Wilcox R, Bousser MG, Betteridge DJ, et al.: Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007, 38:865\u2013873.","journal-title":"Stroke"},{"key":"20_CR48","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","volume":"368","author":"DREAM","year":"2006","unstructured":"DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096\u20131105.","journal-title":"Lancet"},{"key":"20_CR49","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/S0140-6736(07)60824-1","volume":"369","author":"R.L. Krall","year":"2007","unstructured":"Krall RL: Cardiovascular safety of rosiglitazone. Lancet 2007, 369:1995\u20131996.","journal-title":"Lancet"},{"key":"20_CR50","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"S.E. Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise MA, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427\u20132443.","journal-title":"N Engl J Med"},{"key":"20_CR51","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00125-005-1869-1","volume":"48","author":"P.D. Home","year":"2005","unstructured":"Home PD, Pocock SJ, Beck-Nielsen H, et al.: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005, 48:1726\u20131735.","journal-title":"Diabetologia"},{"key":"20_CR52","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","volume":"296","author":"T. Mazzone","year":"2006","unstructured":"Mazzone T, Meyer PM, Feinstein SB, et al.: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006, 296:2572\u20132581.","journal-title":"JAMA"},{"key":"20_CR53","doi-asserted-by":"publisher","first-page":"E5","DOI":"10.1016\/S0002-8703(03)00146-7","volume":"146","author":"T. Takagi","year":"2003","unstructured":"Takagi T, Yamamuro A, Tamita K, et al.: Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003, 146:E5.","journal-title":"Am Heart J"},{"key":"20_CR54","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.2337\/diacare.27.11.2654","volume":"27","author":"D. Choi","year":"2004","unstructured":"Choi D, Kim SK, Choi SH, et al.: Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004, 27:2654\u20132660.","journal-title":"Diabetes Care"},{"key":"20_CR55","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"S.E. Nissen","year":"2007","unstructured":"Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457\u20132471.","journal-title":"N Engl J Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-008-0020-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-008-0020-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-008-0020-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-008-0020-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T21:32:09Z","timestamp":1744147929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-008-0020-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["20"],"URL":"https:\/\/doi.org\/10.1007\/s11883-008-0020-4","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"type":"print","value":"1523-3804"},{"type":"electronic","value":"1534-6242"}],"subject":[],"published":{"date-parts":[[2008,4]]},"assertion":[{"value":"6 April 2008","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}